(and dosage form):
Each tablet contains: 135 mg mebeverine hydrochloride.
A 11.2: Gastro-intestinal antispasmodics and cholinolytics.
Bevispas is a musculotropic spasmolytic agent with a selective action especially on smooth muscle spasms of the gastro-
intestinal tract. No significant inhibition of normal peristalsis has been observed.
Primary irritable colon characterised by persistent diarrhoea, alternating constipation and diarrhoea, abdominal pain and
postprandial distension. Secondary irritable colon due to organic lesions such as diverticulitis, regional enteritis, specific
and non-specific inflammatory conditions of the gastro-intestinal tract.
Hypersensitivity to any ingredient in the product. Patients with porphyria.
DOSAGE AND DIRECTIONS FOR USE:
135 mg mebeverine hydrochloride (one tablet) three times daily, preferably before meals. After a period of a few weeks
the dosage may be gradually reduced once the desired effect has been obtained. Mebeverine hydrochloride is not contra-
indicated in patients with glaucoma or prostatic hypertrophy, as atropine-like effects are absent.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Depression, headache, diarrhoea, constipation and dizziness have been reported after administration of Bevispas.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
See Side Effects and Special Precautions. Treatment is symptomatic and supportive.
A white biconvex film coated tablet engraved with a mortar and pestle on one side.
Securitainer packs of 100 tablets.
Securitainer packs of 20 tablets.
Securitainer packs of 500 tablets.
Store below 30°C in tightly closed containers. Protect from light.
KEEP OUT OF REACH OF CHILDREN.
NAME AND BUSINESS ADDRESS OF APPLICANT:
7 Fairclough Road
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
A & S PRINTERS.
Updated on this site: January 2001
Current: April 2005
Source: Community Pharmacy
To get the complete Patient Information Leaflet, access information on other formulations and dosages and get safety alerts register for free on myHealthbox.
JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Evista (raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product...